Pharmaceutical Titan Pfizer (PFE) – Get report said “there is no data” to show that a single dose of his coveted vaccine offers protection against infection beyond 21 days, a media report said.
Pfizer told Axios that some protection appears to begin 12 days after the first dose.
But the New York health giant also said that two doses of the vaccine, separated by three weeks, represent the only treatment that has been shown to be 95% effective in Phase 3 tests, reports Axios.
He said it is important because the UK National Health Service has announced a change in its vaccine approach “to give the first dose to as many people in risk groups as possible, rather than providing the two necessary doses in the shortest possible time. . “
The NHS said, “Everyone will still receive their second dose, and that will be within 12 weeks of the first. The second dose completes the course and is important for long-term protection.”
Pfizer shares were recently traded at $ 36.44, down 0.8%. They fell 1.8% this year, as investors do not see their finances benefiting much from the vaccine.
Morningstar analyst Damien Conover sees the shares as somewhat undervalued, putting the fair value at $ 40.
“We believe that the incredible speed of the vaccine for the market reinforces [the] innovative power behind Pfizer’s large gap, ”he wrote this month.
But “we expect strong competition for vaccines from” other companies, “which is likely to stop the pandemic significantly, but will also reduce the profitability of the covid-19 vaccine market,” said Conover.
“We expect vaccine pricing power to be low with so many potential competitors.”